Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Vimovo Articles

European Patent Office maintains Pozen's PA/Vimovo patent

12 March 2013

AstraZeneca and Pozen sue Dr Reddy’s over Vimovo patent

27 April 2011

AstraZeneca gets EU backing for OA/RA drug Vimovo; Merck KGaA appeals EMEA decision on cladribine for MS

11 October 2010

Pozen gets $20 million milestone from AstraZeneca as a result of FDA approval of Vimovo

27 May 2010

US FDA warns of fracture risks with proton pump inhibitors; calls for class labeling change

26 May 2010

AstraZeneca/Pozen’s Vimovo combo drug cleared by US FDA, pushing US firm’s stock up 21%; AZ expands deal with Targacept

4 May 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS